Literature DB >> 169393

Plaque assay of avian sarcoma viruses using casein.

P C Balduzzi, H Murphy.   

Abstract

The caseinolytic activity of several strains of Rous sarcoma virus (RSV), conditional and nonconditional mutants of RSV, and nontransforming avian leukosis viruses was investigated. Only those viruses capable of transforming chick fibroblasts in vitro induced lysis of casein incorporated into an agar overlay. Lysis produced distinct clear areas in the turbid casein-agar gel which allowed a quantitative "plaque" assay of cell transformation. Casein plaque formation could not be separated from morphological conversion in cultures infected by wild-type RSV strains. In plates infected by mutants temperature sensitive for transformation, the caseinolytic activity appeared to be affected by temperature to a lesser extent than morphological conversion.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 169393      PMCID： PMC354718     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  8 in total

1.  CLONAL GROWTH OF MAMMALIAN CELLS IN A CHEMICALLY DEFINED, SYNTHETIC MEDIUM.

Authors:  R G HAM
Journal:  Proc Natl Acad Sci U S A       Date:  1965-02       Impact factor: 11.205

2.  The control of cellular morphology in embryonic cells infected with rous sarcoma virus in vitro.

Authors:  H M TEMIN
Journal:  Virology       Date:  1960-02       Impact factor: 3.616

3.  Temperature-sensitive avian sarcoma viruses: a physiological comparison of twenty mutants.

Authors:  J A Wyke; M Linial
Journal:  Virology       Date:  1973-05       Impact factor: 3.616

Review 4.  Envelope classification of avian RNA tumor viruses.

Authors:  P K Vogt
Journal:  Bibl Haematol       Date:  1970

5.  Increased protease levels in transformed cells: a casein overlay assay for the detection of plasminogen activator production.

Authors:  A R Goldberg
Journal:  Cell       Date:  1974-06       Impact factor: 41.582

6.  A plaque assay for avian RNA tumor viruses.

Authors:  T Graf
Journal:  Virology       Date:  1972-11       Impact factor: 3.616

7.  An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses.

Authors:  J C Unkeless; A Tobia; L Ossowski; J P Quigley; D B Rifkin; E Reich
Journal:  J Exp Med       Date:  1973-01-01       Impact factor: 14.307

8.  Mechanism of oncogenic transformation by Rous sarcoma virus. I. Intracellular inactivation of cell-transforming ability of Rous sarcoma virus by 5-bromodeoxyuridine and light.

Authors:  P Balduzzi; H R Morgan
Journal:  J Virol       Date:  1970-04       Impact factor: 5.103
  8 in total
  6 in total

1.  Cooperative transformation studies with temperature-sensitive mutants of Rous sarcoma virus.

Authors:  P C Balduzzi
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

2.  Distinguishable transformation-defective phenotypes among temperature-sensitive mutants of Rous sarcoma virus.

Authors:  D Becker; R Kurth; D Critchley; R Friis; H Bauer
Journal:  J Virol       Date:  1977-03       Impact factor: 5.103

3.  Lack of correlation between tumorigenicity and level of plasminogen activator in fibroblasts transformed by Rous sarcoma virus.

Authors:  B A Wolf; A R Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

4.  Biological properties of "partial" transformation mutants of Rous sarcoma virus and characterization of their pp60src kinase.

Authors:  D D Anderson; R P Beckmann; E H Harms; K Nakamura; M J Weber
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

5.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

6.  Antibody-mediated neutralization of virus is abrogated by mycoplasma.

Authors:  C Dickson; J Elkington; A Hales; R Weiss
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.